Garenoxacin

Jump to: navigation, search
Garenoxacin
Garenoxacin.png
Clinical data
Routes of
administration
Oral
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H20F2N2O4
Molar mass426.412 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Garenoxacin

Articles

Most recent articles on Garenoxacin

Most cited articles on Garenoxacin

Review articles on Garenoxacin

Articles on Garenoxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Garenoxacin

Images of Garenoxacin

Photos of Garenoxacin

Podcasts & MP3s on Garenoxacin

Videos on Garenoxacin

Evidence Based Medicine

Cochrane Collaboration on Garenoxacin

Bandolier on Garenoxacin

TRIP on Garenoxacin

Clinical Trials

Ongoing Trials on Garenoxacin at Clinical Trials.gov

Trial results on Garenoxacin

Clinical Trials on Garenoxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Garenoxacin

NICE Guidance on Garenoxacin

NHS PRODIGY Guidance

FDA on Garenoxacin

CDC on Garenoxacin

Books

Books on Garenoxacin

News

Garenoxacin in the news

Be alerted to news on Garenoxacin

News trends on Garenoxacin

Commentary

Blogs on Garenoxacin

Definitions

Definitions of Garenoxacin

Patient Resources / Community

Patient resources on Garenoxacin

Discussion groups on Garenoxacin

Patient Handouts on Garenoxacin

Directions to Hospitals Treating Garenoxacin

Risk calculators and risk factors for Garenoxacin

Healthcare Provider Resources

Symptoms of Garenoxacin

Causes & Risk Factors for Garenoxacin

Diagnostic studies for Garenoxacin

Treatment of Garenoxacin

Continuing Medical Education (CME)

CME Programs on Garenoxacin

International

Garenoxacin en Espanol

Garenoxacin en Francais

Business

Garenoxacin in the Marketplace

Patents on Garenoxacin

Experimental / Informatics

List of terms related to Garenoxacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Garenoxacin (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.

Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China.

On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review.[1]

Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.[2]

The European Medicines Agency (EMEA) had also been formally notified by Schering-Plough Europe (July 28 2007) of its decision to withdraw the application for a centralized marketing authorization for garenoxacin as well.[3][4][5] Based on the CHMP review of the data regarding safety and efficacy (risk/benefit), the CHMP considered the application for garenoxacin to be unapprovable.[6]

References

  1. "Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review". Retrieved 2008-03-25.
  2. http://www.fiercebiotech.com/story/schering-plough-pulls-its-garenoxacin-app/2006-08-21
  3. http://www.medicalnewstoday.com/articles/78052.php
  4. http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/34117407en.pdf
  5. http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf
  6. http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf

Linked-in.jpg